Despite the considerable efficacy of anti-Tumor Necrosis Factor (TNF)-α monoclonal antibody (mAb) therapy in the treatment of inflammatory bowel disease (IBD), about one third of patients do not respond (1). This evidence concerns the gene TNF and inflammatory bowel disease.